Closed or Open Abdomen for the Management of Abdominal Sepsis
Launched by UNIVERSITY OF CALGARY · May 19, 2017
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods for treating a serious condition called abdominal sepsis, which is an infection in the abdomen that can be life-threatening. The trial will randomly assign participants to one of two groups: one group will have their abdomen closed after surgery (this is called the CLOSED approach), while the other group will have their abdomen left open and covered with a temporary device that helps manage the infection (this is known as the OPEN approach). Both methods are currently accepted treatments, but the trial aims to gather better information to help doctors make the best choice for their patients.
To be eligible for this trial, participants must be between the ages of 65 and 74 and have specific signs of a severe abdominal infection, such as a significant amount of infected fluid in the abdomen or symptoms indicating severe illness. People who are pregnant, have certain serious conditions, or are not planning to continue receiving medical care cannot participate. Those who join the trial can expect to receive close monitoring and care while doctors assess which treatment method is more effective in managing their condition. This research is important because it will provide valuable insights that could help improve outcomes for patients with abdominal infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presence of purulent, feculent, or enteric spillage over at least 2 intra-peritoneal quadrants intra-operatively;
- • Septic shock, or
- • Predisposition-Infection-Response-Organ Dysfunction Score \> 3, or
- • World-Society-of-Emergency-Surgery-Sepsis-Severity-Score \> 8
- Exclusion Criteria:
- • Pregnant;
- • Confirmed or strongly suspected severe IAH (IAP\>20 mmHg);
- • No intentional of providing ongoing care;
- • pancreatitis as the source of peritonitis;
- • uncontrolled bleeding
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Patients applied
Trial Officials
Andrew W Kirkpatrick, MD
Principal Investigator
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials